Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) — Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced making Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) in connection with the employment and appointment of John Manning to the position of Area Vice President of Sales. Mr. Manning will report to Doris Quackenbush, Vice President of Sales.
Related news for (AXGN)
- Axogen Announces Chief Financial Officer Transition
- Axogen, Inc. Reports 2025 First Quarter Financial Results
- Axogen, Inc. Reports 2024 Fourth Quarter and Full-Year Financial Results
- Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024
- axogen completes submission of biologics license application to u.s. food and drug administration for avance nerve graft®
